Mission Statement, Vision, & Core Values of Compugen Ltd. (CGEN)

Compugen Ltd.'s (CGEN) foundational mission-to discover novel drug targets and develop innovative cancer treatments-is the true engine behind its operations, especially when you look at the Q3 2025 financials. The biotech is spending aggressively to chase that mission, reporting R&D expenses of approximately $5.8 million in the third quarter alone, which is over three times its Q3 2025 revenue of $1.9 million. Does a strong strategic blueprint justify that kind of cash burn, and how does their commitment to a high standard and ownership translate into a cash runway into Q3 2027?

Compugen Ltd. (CGEN) Overview

Compugen Ltd. is a clinical-stage cancer immunotherapy company, but its real edge is its proprietary, predictive computational discovery platform, Unigen™. This platform is what transformed the company from a computational biology firm into a therapeutic discovery powerhouse, identifying novel drug targets for cancer treatment.

The company's product pipeline is focused on immuno-oncology (I-O), which uses the body's own immune system to fight cancer. Their key wholly-owned clinical assets include COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class anti-TIGIT antibody, both aimed at treating solid tumors.

As of late 2025, Compugen is a pre-commercial company, so its sales aren't from product prescriptions; they're from strategic collaborations. Here's the quick math: the company's trailing twelve-month (TTM) revenue as of September 30, 2025, stood at around $6.9 million. This revenue stream is defintely a result of licensing agreements and milestone payments from their major pharmaceutical partners.

• Unigen™ platform drives drug discovery.
• Pipeline includes COM701 and COM902.
• TTM revenue is $6.9 million from collaborations.

Analyzing Q3 2025 Financial Performance

You need to look past the top-line revenue number to understand the financial reality of a clinical-stage biotech. Compugen's latest report, released November 10, 2025, showed third-quarter revenue of approximately $1.9 million. That's a significant drop from the roughly $17.1 million reported in the comparable 2024 period, but this volatility is normal because their revenue is milestone-based, not recurring product sales.

For the first nine months of 2025, total sales were approximately $5.43 million. The company reported a net loss of approximately $6.98 million for Q3 2025, or $0.07 per basic and diluted share. This is a wider loss compared to the net profit of $1.28 million in Q3 2024. But still, the company is in a strong financial position to fund its critical clinical trials.

The crucial number here isn't the quarterly loss-it's the cash position. Compugen reported a solid cash reserve of approximately $86.1 million as of September 30, 2025. This cash runway is projected to fund operations well into the third quarter of 2027, giving them ample time to reach key clinical milestones for their proprietary assets like COM701.

Compugen: A Leader in Computational Immuno-Oncology

The reason Compugen is considered a leader in its niche-computational immuno-oncology (I-O)-comes down to the validation of its Unigen™ platform through major partnerships. They are a pioneer in using artificial intelligence and machine learning (AI/ML) to discover novel immune checkpoints, which are the next generation of I-O targets.

Their success is best mapped by their deals with pharmaceutical giants. The TIGIT component of AstraZeneca's rilvegostomig, which is now in Phase 3 trials, was derived from Compugen's COM902. Also, their asset GS-0321 (previously COM503) is licensed to Gilead. These partnerships, including potential milestones and royalties, carry a combined value of over $1 billion. That kind of financial commitment from industry leaders is the clearest sign of Compugen's strategic importance.

The advancement of their proprietary COM701 into the MAIA-ovarian blinded randomized maintenance trial, enrolling patients across the U.S., Israel, and France, further solidifies their clinical leadership. They are translating computational discovery into tangible clinical progress. To understand the institutional conviction behind this success, you should look at Exploring Compugen Ltd. (CGEN) Investor Profile: Who's Buying and Why?

Compugen Ltd. (CGEN) Mission Statement

You're looking for the bedrock of Compugen Ltd.'s (CGEN) investment thesis, and honestly, it all starts with their mission. A mission statement isn't just corporate fluff; it's the strategic filter for every dollar spent, especially in a capital-intensive industry like biotech. Compugen's mission is clear: to discover novel drug targets and develop innovative cancer treatments to extend the reach of immunotherapies to new patient populations. That last part-extend the reach-is the critical takeaway for investors, signaling a focus on underserved patient groups and novel mechanisms of action.

Their long-term goal is to shift the cancer treatment landscape, and this mission guides their financial allocation. For example, the company reported a net loss of approximately $6.98 million in the third quarter of 2025, a number that tells you they are still firmly in the R&D-heavy, value-creation phase, not the commercial-profit phase. Still, their cash position of approximately $86.1 million as of September 30, 2025, gives them a runway into 2027 to execute on this mission without immediate financing pressure.

Core Component 1: Predictive Computational Discovery (High Standard)

The first pillar of Compugen's mission is their 'High Standard' core value, which translates directly into their proprietary engine: Predictive Computational Discovery. This is where the company differentiates itself from traditional biotech. They use their broadly applicable predictive AI/ML-powered computational discovery platform, Unigen™, to identify new drug targets and biological pathways.

This commitment to excellence in discovery is backed by tangible investment. Compugen's Research and Development (R&D) expenses were approximately $5.8 million for the third quarter of 2025. Here's the quick math: that R&D expense represents over three times the Q3 2025 revenue of approximately $1.9 million, showing a clear prioritization of future discovery over near-term revenue. This focus on computational biology is defintely the engine for their pipeline, allowing them to find targets like PVRIG that others missed.

• Use AI/ML to identify novel drug targets.
• Maintain a high standard of rigorous experimental processes.
• Invest heavily in the Unigen™ platform.

Core Component 2: Differentiated Pipeline Development (Ownership)

The second component, rooted in their 'Ownership' core value, is the commitment to advancing a differentiated pipeline of first-in-class therapeutics. This means taking full responsibility for their programs and their ultimate success or failure. The company is not just discovering targets; they are developing them into clinical-stage assets like COM701 and COM902.

The key here is the differentiation. For example, Compugen focuses on Fc-reduced anti-TIGIT antibodies, like their fully owned COM902, because they believe this format preserves beneficial T cells and avoids the depletion of peripheral T-regs, offering a potentially improved efficacy and safety profile over competitors' Fc-active versions. This isn't just theory; it's being tested in the clinic right now. In July 2025, the first patient was dosed in the MAIA-ovarian platform trial evaluating COM701 maintenance therapy in patients with platinum-sensitive ovarian cancer, a clear action showing pipeline progression.

Core Component 3: Global Partnerships and Patient Focus (Team Work)

The final pillar is leveraging 'Team Work' to accelerate the delivery of innovative treatments to patients globally. For a company of Compugen's size, strategic partnerships are non-negotiable for scaling clinical development and commercialization. This is where their patient focus-extending the reach of immunotherapies-is realized.

Compugen has validated partnerships with major pharmaceutical players like AstraZeneca and Gilead Sciences, which provide not only capital but also global development muscle. These collaborations have the potential to deliver over $1 billion in milestone payments and tiered royalties on future sales. The rilvegostomig program, licensed to AstraZeneca, is already in multiple Phase 3 trials, representing a significant value driver for Compugen and a direct path to bringing a Compugen-discovered therapy to a broad patient population. You can dive deeper into the market's view of this strategy in Exploring Compugen Ltd. (CGEN) Investor Profile: Who's Buying and Why?

Compugen Ltd. (CGEN) Vision Statement

You're looking for the foundational strategy behind Compugen Ltd.'s clinical-stage pipeline, and that starts with their core beliefs. For a biotech company, the Vision and Mission aren't just feel-good marketing; they are the roadmap that justifies burning through cash-which, in Q3 2025, was a net loss of approximately $6.98 million-on research and development (R&D). Their Vision is clear: it's about transforming patient outcomes through their proprietary computational platform.

Here's the quick math: R&D expenses were approximately $5.8 million in the third quarter of 2025, which shows a strong, sustained commitment to this vision. You need to see that spend translate into tangible progress, and Compugen's Vision sets the stage for that return.

Transforming Patient Lives: The Vision

Compugen's Vision is stated as: 'Transforming patient lives by developing first-in-class therapeutics based on Compugen's computational target discovery platform.' That tagline, 'From Code to Cure®,' really sums up the whole approach. It means they start with massive datasets and artificial intelligence/machine learning (AI/ML) to find novel targets, not just incremental improvements.

This computational discovery platform, called Unigen™, is the engine. The goal is to create what they call 'first-in-class' drugs-meaning they are pioneering a new mechanism of action in cancer immunotherapy (IO). This is a high-risk, high-reward strategy, but it's what gives them a cash runway expected to fund operations into 2027, even with Q3 2025 revenue at only approximately $1.9 million.

Expanding Immunotherapy's Reach: The Mission

The Mission is the active verb behind the Vision: 'to discover novel drug targets and develop innovative cancer treatments to extend the reach of immunotherapies to new patient populations.' This is a critical distinction for investors. The current IO landscape, dominated by PD-1/PD-L1 inhibitors, still leaves many cancer patients-the non-responders-without effective options. That's the gap Compugen aims to fill.

Their lead candidate, COM701, an anti-PVRIG antibody, is a perfect example of this mission in action. It's designed to block a newly discovered immune checkpoint (PVRIG), potentially allowing the immune system to attack tumors in patients who don't respond to existing treatments. You can see this focus in their clinical strategy, like the MAIA-ovarian platform trial for COM701 maintenance therapy in platinum sensitive ovarian cancer, which dosed its first patient in July 2025. This is defintely a long game, but the potential is huge.

The Pillars of Execution: Core Values

A bold vision needs a disciplined culture to back it up. Compugen's Core Values aren't abstract; they speak directly to the rigor needed in drug discovery and clinical development. They are the operational framework for managing a cash balance that stood at approximately $86.1 million as of September 30, 2025.

The three core values are:

• High Standard: Strive for excellence; no compromise on quality.
• Ownership: Commitment to success, failures, and thoughtful decisions.
• Team Work: Trust peers; let expertise lead; clear communication.

This emphasis on 'High Standard' and 'Ownership' is especially important in a clinical-stage biotech where a single data point can swing the stock price. It's what drives the meticulous work on their partnered programs, like the rilvegostomig Phase 3 trials being run by AstraZeneca, which could yield over $1 billion in potential milestones and royalties for Compugen. This is why you should be Exploring Compugen Ltd. (CGEN) Investor Profile: Who's Buying and Why?

Compugen Ltd. (CGEN) Core Values

You want to know what truly drives Compugen Ltd. beyond the quarterly earnings, and that's smart. The company's core values aren't just boilerplate text; they are the engine behind their computational target discovery platform and their clinical execution. Their strategy is crystal clear: it's rooted in science and focused on patients, and their actions in 2025 defintely back that up.

We see four primary values guiding their work, all aimed at translating 'Code to Cure®.' These values map directly to their pipeline and their financial commitments, giving you a clear view of their operational priorities.

Pioneering Computational Discovery

This value is about being a pioneer in computational drug target discovery, which is their unique edge in the immuno-oncology (IO) space. They use their predictive AI/ML-powered computational discovery platform, called Unigen™ (a machine learning tool for identifying new drug targets), to find novel biological pathways that others miss. That's the whole business model.

Their commitment here is quantified by their significant investment in research and development (R&D). For the third quarter of 2025 alone, Compugen reported R&D expenses of approximately $5.8 million. That money goes directly into advancing their early-stage pipeline and refining the Unigen™ platform itself. Plus, showing their scientific rigor, they presented research at the Single Cell Genomics 2025 Conference in September, demonstrating their computational capabilities in analyzing the spatial context of complex cancer biology. It's a small company making big bets on data science.

Patient-Centric Impact

Every biotech company talks about helping patients, but for Compugen, this value is about delivering differentiated, meaningful clinical outcomes for hard-to-treat cancers. You can see this focus in their lead proprietary program, COM701, a potential first-in-class anti-PVRIG antibody.

The core action here in 2025 was the initiation of the MAIA-ovarian platform trial, a maintenance immunotherapy trial for patients with relapsed platinum-sensitive ovarian cancer. The first patient was dosed in July 2025. This trial is a direct response to promising Phase 1 data presented at ESMO 2025 in October, which showed a median Progression-Free Survival (PFS) of 10.5 months in patients who derived clinical benefit from COM701. That's a strong, concrete result that informs their next steps, showing they pivot quickly based on patient data.

• Dosed first patient in COM701 maintenance trial in July 2025.
• Pooled Phase 1 data showed 10.5 months median PFS in responders.
• Trial enrollment is ongoing in the U.S., Israel, and France.

Strategic Partnership & Execution

A small clinical-stage company can't do it all, so strategic partnerships are a critical value for Compugen, allowing them to accelerate development and de-risk their pipeline. They choose partners who can execute at a global scale, and the potential financial upside is massive.

The most significant proof points are their alliances with AstraZeneca and Gilead. These partnerships represent over $1 billion in potential milestone payments and tiered royalties, which is a huge vote of confidence in their science. For instance, their anti-IL-18 binding protein antibody, GS-0321, is licensed to Gilead and is progressing through its Phase 1 trial in 2025. Also, AstraZeneca expanded its rilvegostomig program (which uses the TIGIT component derived from Compugen's COM902) to ten active Phase 3 trials in 2025, a clear sign of their partner's execution. That's how you stretch a small balance sheet.

Scientific Excellence & Team Commitment

The final value is about the people and the financial discipline that supports their high-caliber work. They know their computational edge requires a highly committed and talented team performing at the highest level of excellence.

Financially, the company had a cash balance of approximately $86.1 million as of September 30, 2025. This strong balance sheet is expected to fund their operating plans-including all clinical trials and continued investment in the early-stage pipeline-into the third quarter of 2027. This long cash runway shows a commitment to providing the team with the resources and time needed to execute their complex, long-term scientific goals without the constant pressure of near-term financing. They also executed a key leadership transition in September 2025, bringing in a new CEO to bolster corporate strategy and collaboration. You can learn more about the financial implications of this focus in Breaking Down Compugen Ltd. (CGEN) Financial Health: Key Insights for Investors.